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Thomas S. Huber, MD, PhD,a Gainesville, Fla; and Austin, Tex
Objective: The treatment goals of access-related hand ischemia (ARHI) are to reverse symptoms and salvage the access.
Many procedures have been described, but the optimal treatment strategy remains unresolved. In an effort to guide
clinical decision making, this study was undertaken to document our outcomes for distal revascularization and interval
ligation (DRIL) and to identify predictors of bypass patency and patient mortality.
Methods: A retrospective review was performed of all patients who underwent DRIL at the University of Florida from
2002 to 2011. Diagnosis of ARHI was based primarily upon clinical symptoms with noninvasive studies used to
corroborate in equivocal cases. Patient demographics, procedure-outcome variables, and reinterventions were recorded.
Bypass patency and mortality were estimated using cumulative incidence and Kaplan-Meier methodology, respectively.
Cumulative incidence and Cox regression analysis were performed to determine predictors of bypass patency and
mortality, respectively.
Results: A total of 134 DRILs were performed in 126 patients (mean [standard deviation] age, 57 [12] years) following
brachial artery-based access. The postoperative complication rate was 27% (19% wound), and 30-day mortality was 2%.
The wrist-brachial index and digital brachial index increased 0.31 (0.25) and 0.25 (0.29), respectively. Symptoms
resolved in 82% of patients, and 85% continued to use their access. Cumulative incidences (± standard error of the mean)
of loss of primary and primary-assisted patency rates were 5% ± 2% and 4% ± 2% at 1 year and 22% ± 5% and 18% ± 5% at 5
years, respectively, with mean follow-up of 14.8 months. Univariate predictors of primary patency failure were DRIL
complications (odds ratio [OR], 3.3; 95% conﬁdence interval [CI], 1.2-8.9; P [ .02), conﬁguration other than bra-
chiobasilic/brachiocephalic autogenous access (OR, 3.4; 95% CI, 1.4-8.3; P [ .009), and two or more prior access
attempts (OR, 4.1; 95% CI, 1.6-10.4; P [ .004). Brachiocephalic access conﬁguration (OR, 0.2; 95% CI, 0.04-0.8;
P [ .02) and autogenous vein conduit (OR, 0.2; 95% CI, 0.06-0.58; P [ .004) were predictors of improved bypass
patency. All-cause mortality was 28% and 79% at 1 and 5 years, respectively. Multivariable predictors of mortality were
age >40 (hazard ratio [HR], 8.3; 95% CI, 2.5-33.3; P [ .0004), grade 3 ischemia (HR, 2.6; 95% CI, 1.5-4.6; P [
.0008), complication from DRIL (HR, 2.4; 95% CI, 1.3-4.5; P[ .004), and smoking history (HR, 2.2; 95% CI, 1.3-4;
P [ .007). Patients with no prior access attempts had lower predicted mortality (HR, 0.5; 95% CI, 0.3-0.9; P [ .02).
Conclusions: The DRIL procedure effectively improves distal perfusion and reverses the symptoms of ARHI while
salvaging the access, but the long-term survival of these patients is poor. Given the poor survival, preoperative risk
stratiﬁcation is critical. Patients at high risk for DRIL failure and mortality may be best served with alternate remedial
procedures. (J Vasc Surg 2013;57:451-8.)Access-related hand ischemia (ARHI), commonly
known as “steal syndrome,” is one of the most challeng-
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in a predictable decrease in arterial perfusion pressure distal to
the ﬁstula that can lead to ischemia if the compensatory
mechanisms are inadequate. The diagnosis of ARHI is largely
clinical and can be aided in equivocal cases with noninvasive
vascular laboratory studies.1-3 Access-related hand ischemia
occurs in approximately 5% to 20% of brachial artery-based
access procedures, with roughly half classiﬁed as severe and
meriting some type of remedial treatment.3-10 Treatment
goals are to reverse the hand ischemia and preserve the
access while preventing any long-term hand disability.
A variety of remedial treatment strategies have been re-
ported for ARHI, including access ligation, banding (ie,
ﬂow-limiting strategies), bypass, and proximalization of
the arteriovenous anastomosis. The choice is contingent
upon multiple factors, including the severity of symptoms,
patient comorbidities, and the potential utility of the access
itself. The distal revascularization and interval ligation
procedure (DRIL) is our preferred treatment because it451
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approximately 90% of the cases.11 However, several reports
have raised concerns regarding the need for ligation of
the brachial artery, thus leaving distal forearm and hand
perfusion reliant upon a functioning brachialebrachial
bypass.12-14 Furthermore, the postoperative complication
rates after the DRIL can range from 5% to 15%,11,12,15
and primary patency at 2 years is estimated to be 70% to
80%.8,11,12,16 Given these potential issues, the decision
regarding choice of remedial procedure must also consider
the patient’s life expectancy. The 1-year survival rate in our
previous DRIL series was 70%, suggesting that the annual
mortality rate for patients with ARHI may exceed the 20%
to 23% annual rate reported in the United States for all
patients on hemodialysis.11,17
These observations and reported concerns about the
DRIL procedure prompted this analysis in an effort to
guide clinical decision making. This study was undertaken
to evaluate our outcomes for the DRIL procedure and to
identify predictors of bypass patency and patient mortality.
METHODS
Experimental design. All patients undergoing crea-
tion of an upper extremity hemodialysis access between
2002 and 2011 at the University of Florida were identiﬁed.
A prospectively maintained database was queried, and
those patients who had undergone remedial procedures
for ARHI were further studied (126 patients including
the 61 patients previously described by Huber et al11).
Approval for this study was obtained from the Institutional
Review Board.
Clinical practice. A deﬁned and validated algorithm to
optimize the use of autogenous conduit access was followed
by all surgeons.18 All patients underwent noninvasive arterial
and venous imaging preoperatively, and conﬁrmatory inva-
sive arterial and/or venous angiography was used in selected
cases. Hierarchy for the access conﬁgurations followed the
recommendations of the Kidney Disease Outcomes Quality
Initiative (KDOQI)/Society for Vascular Surgery (SVS)
guidelines and our previously published algorithm.19,20
The diagnosis of ARHI was primarily a clinical assess-
ment of the operating surgeon. Selected patients had
undergone noninvasive arterial testing, which included
brachial, radial, ulnar, and digital pressures and velocity
waveform analysis. These data were used to conﬁrm
ARHI diagnosis in equivocal cases. The management of
patients with mild (grade 1) ARHI was expectant, whereas
deﬁnitive remediation was reserved for patients with
moderate (grade 2) or severe (grade 3) ischemia (see Deﬁ-
nitions). Upper extremity digital subtraction arteriography
was used in the majority of cases to determine if there was
a correctable arterial inﬂow stenosis. Decision to proceed
with DRIL followed a published algorithm for manage-
ment of ARHI.21
The DRIL procedure was performed as previously
described.22 The proximal anastomosis of the brachiale
brachial bypass was created$7 cmproximal to the arteriove-
nous anastomosis of the access. The distal anastomosis wasconstructed immediately distal to the access anastomosis,
and the brachial artery was ligated or transected immediately
proximal to the distal bypass anastomosis. The preferred
conduit was greater saphenous vein ($3 mm) with alterna-
tive conduit choices based on conduit availability (arm vein
> femoral vein > cadaveric vein > prosthetic graft). All
attempts were made to preserve upper extremity veins for
potential future access creation. Doppler insonation and
palpation of the radial/ulnar pulse were used to determine
technical adequacy of the bypass. Completion arteriography
or intraoperative duplex scanning was used at case comple-
tion in selected cases at the operating surgeon’s discretion.
Postoperatively, patients were given aspirin (81 mg) (unless
contraindicated) and evaluated with a standardized surveil-
lance protocol. This involved upper extremity pressure/
waveform analysis and duplex scanning of the brachiale
brachial bypass as previously described for our lower
extremity bypasses.11,23 Postoperative duplex surveillance
of the DRIL occurred at 1, 3, 6, 9, and 12 months and
every 6 months thereafter. Reintervention was based on
the presence of recurrent hand symptoms, signiﬁcant
decrease in arterial pressures ($15 mm Hg drop in arterial
wrist pressure), and/or abnormal graft scan (mean graft
velocity <50 cm/s, maximum velocity ratio >3.5).24
Deﬁnitions and data analysis. Comorbidities were
deﬁned and retrospectively recorded as follows: coronary
artery disease (any history of myocardial infarction, angina,
prior coronary intervention, or electrocardiographic changes
consistent with prior myocardial infarction); cerebrovascular
occlusive disease (history of transient ischemic attack, stroke,
and/or prior carotid endarterectomy/stent/angioplasty);
congestive heart failure (chart history, New York Heart
Association class II or greater, diagnosis on preoperative
evaluation); chronic obstructive pulmonary disease (chart
history or preoperative pulmonary function testing consistent
with the diagnosis, medication); diabetes mellitus (chart his-
tory, insulin, oral hypoglycemics); peripheral artery disease
(ankle-brachial index <0.9, chart history, prior peripheral
endovascular intervention or open infrainguinal reconstruc-
tion); hypertension (chart history, antihypertensive medica-
tions, or preoperative blood pressure $140/90 mm Hg);
dyslipidemia (chart history, taking cholesterol-lowering
medications); and smoking history (any prior or current
smoking). Data collection also included preoperative anti-
platelet (aspirin, aspirin þ dipyridamole, or clopidogrel),
anticoagulant (warfarin), and statin medication use.
The DRIL bypass patency was objectively assessed with
duplex ultrasound scanning and/or selective arteriography.
Patient mortality was veriﬁed by query of the Social Secu-
rity Administration’s Death Master File. Preoperative and
postoperative wrist-brachial index (WBI) and digital
brachial index (DBI) were compared with paired t-test,
and P # .05 was accepted as signiﬁcant.
The ARHI was categorized using the SVS reporting
standards as mild (grade 1), moderate (grade 2), or severe
(grade 3).25 Patients categorized as having grade 2 or 3
ischemia presented with a spectrum of symptoms and phys-
ical examination ﬁndings. The predominant (most severe)
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loss > motor dysfunction > rest pain > intermittent,
hemodialysis-dependent rest pain > paresthesia > cool-
ness). Grade 2 ischemia was deﬁned by the presence of
hand coolness, numbness/paresthesia, or intermittent
hand pain while on hemodialysis. Grade 3 ischemia was
deﬁned as rest pain (including while off a hemodialysis
circuit), neuromotor hand dysfunction, or presence of
ulceration/gangrene.
Risk model design. The outcomes of interest were
time to loss of primary or primary-assisted patency, time
to secondary intervention, and time to death. The distribu-
tion of mortality was estimated using the Kaplan-Meier
method. The distributions of the loss of patency
outcomes were summarized using cumulative incidence
functions due to the presence of mortality as a competing
risk with occurrence of DRIL failure.26,27 Cumulative
incidence regression, rather than Cox proportional hazards
regression, was used to study predictors of primary DRIL
patency because mortality and graft failure were considered
to be competing risks.28 In the presence of competing
risks, Kaplan-Meier estimates are inaccurate because this
methodology assumes all events are independent (ie, that
patients who die after DRIL are still at risk for graft failure,
which is clearly false).
For mortality, all possible models with up to ﬁve risk
factors were considered, and the model with the best
measure of the relative goodness of ﬁt (deﬁned as lowest
AIC or “an information criterion” taking into account
the number of risk factors and the ﬁt of a model) was
selected. The maximum number of risk factors considered
in the multivariable model was limited to ﬁve because the
number of mortality events was only 60. No multivariable
models for primary patency were considered given that
there were only 14 events. Statistical analysis was per-
formed using SAS 9.2 (SAS Institute, Cary, NC) and R
2.15.0 (http://www.r-project.org/).
RESULTS
From 2002 to 2011, 2753 access-related procedures
were performed (excluding dialysis catheters), of which
1882 were new access creations. Of these new access proce-
dures, the overall incidence of grade 2 or 3 ARHI requir-
ing remediation was 7.8%. The distribution of permanent
access creations are noted in Fig 1, with the majority based
off the brachial artery. Four patients underwent proximali-
zation, 17 had access ligation, and 126 underwent a
DRIL procedure. Of the patients with an autogenous
brachialecephalic or brachialebasilic upper arm access,
8% underwent DRIL compared with 11% of those with
brachialeaxillary indirect autogenous or cadaveric femoral
vein translocation. In contrast, only 1% with a prosthetic
brachialeaxillary access conﬁguration underwent DRIL,
and no patients with autogenous radialecephalic direct
wrist access required remediation for ARHI.
A total of 134 DRIL operations were performed on
126 patients (mean [standard deviation] age, 57 [12]
years). The mean total time on hemodialysis beforepresenting with ARHI requiring remediation was 26 (41)
months. The majority of patients were female (59%) and
had a preoperative diagnosis of diabetes (69%). Other
demographic and access-related surgical history date are
given in Table I. Thirteen percent of the patients under-
going DRIL had two or more prior access attempts
(deﬁned as any prior access creation operations), and 15%
had a prior clinical diagnosis of ARHI (with or without
remediation). Table II lists the distribution of preoperative
access conﬁgurations and preoperative medication use.
Sixteen percent of the DRIL patients had an autogenous
brachialeaxillary indirect femoral vein translocation,19
and only 2% had a prosthetic brachialeaxillary access.
Before the DRIL procedure, only 10% of patients were
not on any anticoagulation or antiplatelet regimen. More
than half of the patients (53%) were taking a statin medica-
tion at the time of their procedure.
Many patients presented with multiple symptoms and
physical examination ﬁndings consistent with ARHI. The
most severe or predominant indications for DRIL are given
in Fig 2. Sixty-nine percent of patients had grade 3
ischemia. The average time from index access creation to
DRIL was 82 6 153 days (Fig 3). A planned, preemptive
DRIL (performed at time of index access procedure) was
performed in eight patients (6%) because of a prior history
of ARHI (n ¼ 6) or known severe, distal forearm occlusive
disease (n ¼ 2). Conduit use for the DRIL brachiale
brachial artery bypass was greater saphenous vein in 75%,
arm vein 18%, composite autogenous vein 3%, cadaveric
vein or artery 3%, and prosthetic graft 1%.
During the DRIL procedure, 5.5% (n ¼ 7) had adjunc-
tive procedures performed (subclavian angioplasty and/or
stent, n ¼ 5; central vein venoplasty, n ¼ 2). Average post-
operative length of stay was 4.2 6 4.8 days. The overall
composite postoperative procedure complication rate was
27%, with the majority attributable to wound infection
(Table III). Thirty-day mortality was 2%, and mean
follow-up is 14.8 (17.6) months (median, 7 months; range,
0-81 months). Signiﬁcant increases in mean WBI and DBI
were detected between the preoperative and postoperative
measurements (WBI: 0.31 [0.25]; P ¼ .02; DBI: 0.25
[0.29]; P ¼ .03; Fig 4). Symptoms fully resolved in 82%
of patients (Fig 5), and 85% continued to use the index
hemodialysis access for which the DRIL was performed
at time of last follow-up.
Patency results and prediction. Cumulative inci-
dences of loss of primary and primary-assisted patencies
of the DRIL bypass (6 standard error of the mean) were
5%6 2% and 4%6 2% at 1 year, and 22% 6 5% and 18%6
5% at 5 years (Fig 6). Univariate predictors of primary
patency failure are given in Table IV. No multivariable
analysis for DRIL patency was attempted due to the low
number of patency failure events.
DRIL reintervention and outcome. Median time to
any reintervention (including repeat DRIL procedures) was
9.4 months (range, 0.2-16.4 months), and cumulative
incidence of reintervention was 15% 6 6% at 1 year and
21% 6 7% at 5 years. Three patients had primary-assisted
Table I. Patient demographic information, comorbid
conditions, and prior access history (including access-
related hand ischemia)
Demographics n ¼ 126
Age, mean (SD), years 57 (12)
Gender (% female) 59%
Comorbidities
Hypertension 95%
Diabetes 69%
Dyslipidemia 55%
Coronary artery disease 49%
Smoking 46%
Congestive heart failure 21%
Prior hand ischemia 15%
Prior access attempts ($2) 13%
SD, Standard deviation.
Table II. Distribution of access conﬁgurations and
preoperative antiplatelet, anticoagulation, and statin use
among patients who underwent distal revascularization
and interval ligation (DRIL)
Access conﬁgurations n ¼ 126
Autogenous brachialecephalic upper arm direct
access
46%
Autogenous brachialebasilic upper arm
transposition
36%
Autogenous/cadaveric brachialeaxillary indirect
femoral vein
16%
Prosthetic brachialeaxillary access 2%
Preoperative medication use
Aspirin 84%
Statin 53%
No anticoagulation/antiplatelet 10%
Clopidogrel 20%
Warfarin 14%
Fig 2. Predominant indication for distal revascularization and
interval ligation (DRIL) procedure. A few patients underwent
DRIL at the time of index access creation due to prior access-
related hand ischemia and are not represented in this graph.
Fig 1. Absolute numbers and proportions of new access conﬁgurations performed between 2002 to 2011.
JOURNAL OF VASCULAR SURGERY
454 Scali et al February 2013patency events occurring at 1 (subclavian stent), 61
(angioplasty of proximal anastomosis), and 367 (angio-
plasty of distal anastomosis) days after the initial DRIL
operation. Of the 11 patients who had documented bra-
chialebrachial bypass occlusion, three were asymptomatic,and eight patients underwent a second DRIL procedure at
a median interval of 10.2 months (range, 0.2-16.4
months). No patient with a brachialebrachial bypass un-
derwent graft thrombectomy or thrombolysis with revision
(ie, no secondary patency events). Of the eight patients
who underwent a second DRIL procedure, six (75%) were
patent at the time of this analysis. Two patients with a
patent second DRIL had mild, residual paresthesia, and
one patient with two failed DRIL operations had perma-
nent neurologic hand dysfunction secondary to ischemic
monomelic neuropathy that was retrospectively determined
to be present before the initial DRIL occlusion. No minor
or major amputations resulted from DRIL thrombosis.
Mortality prediction. All-cause mortality was 28% 6
5% at 1 year and 79% 6 6% at 5 years (Fig 7). Multivari-
able predictors of mortality are listed in Table V. Predictors
of mortality after DRIL were age >40 years, grade 3
ischemia, any complication after DRIL, and any smoking
history. If patients had no prior hemodialysis access
Fig 3. Performance of distal revascularization and interval ligation
(DRIL) procedure in days after the index access creation.
Table III. Thirty-day morbidity and mortality after distal
revascularization and interval ligation (DRIL)
Morbidity 27%
Wound 19%
Peripheral nerve 3%
Cardiac 2%
Gastrointestinal 2%
Cerebrovascular 1%
Thirty-day mortality 2%
Fig 4. Mean preoperative (Pre-op) and postoperative (Post-op)
wrist-brachial index (WBI) and digital brachial index (DBI).
Signiﬁcant increases were noted for both indices following distal
revascularization and interval ligation (DRIL) (*P < .05). Pre-
operative hemodynamic data were available for 75% (n ¼ 95) of
cases, whereas 68% (n ¼ 86) had at least one postoperative duplex
scan of the graft with WBI/DBI measurements.
Fig 5. Proportion of patients with complete symptom resolution
following distal revascularization and interval ligation (DRIL) and
of patients with residual paresthesia, motor dysfunction, or tissue
loss following DRIL.
Fig 6. Cumulative incidences of the loss of primary patency of the
distal revascularization and interval ligation (DRIL) bypass. The
standard errors were <10% throughout the time interval repre-
sented. Numbers of patients at risk are given beneath the curve.
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DRIL operation was performed), improved survival was
predicted.DISCUSSION
The results of this study highlight the safety and efﬁ-
cacy of the DRIL procedure for management of ARHI
and elucidate risk factors that have an impact on bypass
patency and predict patient mortality. The beneﬁts of
DRIL in relieving the symptoms of ARHI while simulta-
neously preserving the access for hemodialysis are substan-
tial, as >80% of patients had complete symptom relief and
were still utilizing their access at time of last follow-up.
These ﬁndings are corroborated by the demonstrated
hemodynamic beneﬁts, with signiﬁcant improvements in
both WBI and DBI after DRIL.
The hemodynamic basis for the DRIL procedure is the
low-resistance arterial bypass that overcomes the high-
resistance collateral circulation and the ligation that
prevents retrograde ﬂow from the distal vessels through
the ﬁstula. Interestingly, the components that afford
the hemodynamic advantage (ie, arterial bypass, ligation)
have also been cited as limitations of this procedure.
Concerns have been raised of the possibility of catastrophic
outcomes with DRIL thrombosis due to the bypass-
dependent hand perfusion. The patency rates demonstrated
Table IV. Univariate predictors of loss of distal revascularization and interval ligation (DRIL) primary patency
Predictora HR CI P value
$2 prior access creations 4.1 1.6-10.4 .004
Nonautogenous brachialecephalic/brachialebasilic accessb 3.4 1.4-8.3 .009
Complication from DRIL 3.3 1.2-8.9 .02
Autogenous vein conduit 0.2 0.06-0.58 .004
Autogenous brachialecephalic upper arm direct access 0.2 0.04-0.8 .02
CI, Conﬁdence interval; HR, hazard ratio.
aCumulative incidence regression was used to determine univariate associations between patient covariates and DRIL bypass primary patency. Cumulative
incidence regression was used due to the competing risk of patient mortality.
bNonautogenous brachialecephalic/brachialebasilic access includes conﬁgurations of autogenous indirect femoral vein translocation brachialeaxillary access,
cadaveric femoral artery/vein brachialeaxillary access, and prosthetic brachialeaxillary access.
Fig 7. Kaplan-Meier curve for patient survival. The standard
errors were <10% throughout the time interval represented.
Numbers of patients at risk are given beneath the curve. C.I.,
Conﬁdence interval.
Table V. Independent predictors of all-cause patient
mortality after distal revascularization and interval ligation
(DRIL) determined using multivariable Cox proportional
hazard regression analysis
Predictora HR CI
P
value
Age >40 years 8.3 2.5-33.3 .0004
Grade 3 ischemia 2.6 1.5-4.6 .0008
Complication from DRIL 2.4 1.3-4.5 .004
Smoking history (past/current) 2.2 1.3-4 .007
No prior access procedures 0.5 0.3-0.9 .02
CI, Conﬁdence interval; HR, hazard ratio.
aCox proportional hazard regression analysis.
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patency rate >80%. Furthermore, of the 11 patients in our
series who had DRIL thrombosis, none underwent amputa-
tion and only one had permanent hand dysfunction that pre-
dated the index DRIL procedure. Thus, the concerns for
catastrophic complication with DRIL thrombosis may be
unfounded. Unfortunately, the observed hemodynamic
beneﬁts of the DRIL procedure failed to relieve all of the
precipitating neurologic complaints, as a small subset of
patients had persistent paresthesias. We hypothesize that
these patients likely had a severe, irreversible ischemic nerve
injury before DRIL.29 It has been our anecdotal impression
that this irreversible nerve injury can occur fairly quickly in
terms of the time elapsed from access creation and suggests
the importance in the timing of DRIL.
Several univariate associations with primary patency
failure were found in this analysis. As noted earlier, it was
impossible to evaluate the independent inﬂuence of each
factor on DRIL patency due to the small number of events.
However, these associations still merit discussion. The obser-
vations that two or more prior access creations and access
conﬁgurations other than autogenous brachialecephalic or
brachialebasilic upper armaccesswere predictive of decreasedDRIL patency may be due to several factors. The majority of
these patients had a brachialeaxillary indirect access conﬁgu-
ration with either translocated (autogenous or cadaveric)
femoral vein or, rarely, polytetraﬂuroethylene. This likely
selected for a subgroup of patients who were dependent
on hemodialysis for a longer duration and/or one with
multiple prior failures, potentially due to the presence of
more severe forearm arterial occlusive disease or poor vein
graft remodeling.
The use of autogenous conduit was found to be protec-
tive of primary graft patency. The protective association of
this factor is consistent with reports of its impact on lower
extremity bypass patency.30 We noted this association
some time ago, and. since 2009, we have largely abandoned
the use of cadaveric conduit. Similar to lower extremity
bypasses, the greater saphenous vein from the thigh is our
preferred conduit, with $3 mm our diameter criterion for
a suitable vein.18 We are reluctant to harvest the saphenous
vein below the knee in patients with signiﬁcant peripheral
vascular disease due to concerns with wound healing. In
patients who do not have suitable saphenous vein, we have
used the cephalic or basilic vein in select cases, attempting
to balance the beneﬁt of preserving the current access against
the loss of a future access option.
The DRIL procedure has been our preferred choice for
ARHI given our favorable results. However, several other
alternatives may play a role in speciﬁc scenarios. For patients
who lack suitable autogenous conduit, proximalization of
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a reasonable alternative to ligation.31,32 Others have
described a variant of the “proximalization” approach by
complete mobilization of the venous outﬂow track (ie, the
entire cephalic vein from the antecubital fossa to the
shoulder) and translocating this in a looped conﬁguration
with the anastomosis based on the proximal brachial artery
to obviate the use of a prosthetic conduit.10,31 Our own
experience with the proximalization of the arterial inﬂow
procedure has been limited, and we echo conclusions by
Zanow et al31 that it likely is ineffective in patients with
severe tissue loss. We have not performed any revision using
distal inﬂow procedures but have been struck by the lower
incidence of ARHI in access procedures performed using
the proximal radial artery as opposed to the brachial artery
at the antecubital fossa.33 Our enthusiasm for the ﬂow-
limiting approaches is tempered by the inconsistent reports
in the literature and the requisite, tenuous balance between
adequate distal perfusion and sufﬁcient access ﬂow to sustain
effective dialysis. However, the various ﬂow-limiting strate-
gies may be effective for patients who have very high ﬂow
rates, particularly those with cardiac dysfunction.34
The management of ARHI really begins during the
initial evaluation before the index access procedure. All
available strategies should be used to reduce this adverse
outcome, including originating the arteriovenous anasto-
mosis as distal on the arterial tree as possible and conﬁrm-
ing the absence of an arterial inﬂow stenosis. We follow the
KDOQI/SVS guidelines35 and our own well-deﬁned algo-
rithm to optimize the use of autogenous conduit for access
creation18 that prioritize radial artery over brachial artery
inﬂow. Patients are evaluated with both arterial and venous
noninvasive duplex imaging in contrast with many practices
that just focus on the quality of the vein. In addition, for
patients estimated to be at particularly high risk for
ARHI (eg, those with a previous history of hand ischemia
or documented evidence of severe forearm occlusive
disease and cases using large-diameter, compliant conduit
such as translocated autogenous femoral vein), we have
performed simultaneous access creation and DRIL proce-
dures. In other high-risk patients, we have performed
a preoperative saphenous vein survey to identify a suitable
conduit for DRIL before the index access creation.
Dialysis patients are known to have poor long-term
survival in comparison with the general population, as docu-
mented by the United States Renal Data System. In fact, in
2010 the United States Renal Data System reported a strik-
ingly high 20% annual mortality for all hemodialysis
patients.36 Our data suggest that patients with ARHI may
represent a population at even higher risk, with a 1-year
mortality of nearly 30% after the DRIL procedure. We do
not believe the DRIL procedure contributes to this higher
mortality but rather that patients with ARHI have an
increased number and severity of comorbid conditions,
including longer dependence on hemodialysis, that likely
lead to poorer survival. Our analysis demonstrated that
age >40, any smoking history, and grade 3 ischemia all
were independently predictive of increased mortality.Unfortunately, none of these identiﬁed predictors can be
modiﬁed to reduce risk in the preoperative setting. This novel
survival ﬁnding may be better applied in the selection of
patients for DRIL or patient counseling of risks and beneﬁts.
The study has several limitations that merit further
discussion. The retrospective nature of our data collection
likely leads to an underestimation of the incidence of
hand ischemia and precludes an accurate assessment of
the disease severity of both the hand ischemia and the
underlying patient comorbidities. It is conceivable that
several of our access patients developed ARHI and had
their remedial procedures performed at outside institu-
tions, although this is unlikely given our access referral
practice. In addition, there was an inherent selection bias
that had an impact on which access and which remedial
procedure were performed. This is evident in the lack of
a comparative alternative remedial strategy to DRIL in
our series. Complication from DRIL was identiﬁed as
a risk factor for primary patency failure and mortality but,
unfortunately, cannot be determined preoperatively to
guide decision making. The development of a prediction
model for complication after DRIL may be important in
deﬁning a subset of patients with higher concurrent risk
of perioperative complication, DRIL failure, and all-cause
mortality. This is the subject of a future analysis and may
further identify patients who would be best served with
alternative remedial operations for management of ARHI.
CONCLUSIONS
The DRIL procedure effectively improves distal perfu-
sion and reverses the symptoms of ARHI while salvaging
the access. Avoidance of nonautogenous conduit use is
important to achieve good outcomes. All-cause mortality
after DRIL is high, and, given the high mortality of this
patient population, preoperative risk stratiﬁcation is critical
for optimal utilization of this remedial strategy. Patients at
high risk for DRIL failure and mortality may be best served
with alternate remedial procedures.
AUTHOR CONTRIBUTIONS
Conception and design: SS, CC, TH
Analysis and interpretation: SS, CC, TH
Data collection: SS
Writing the article: SS, CC, TH
Critical revision of the article: SS, CC, DR, MD, AB, RF,
SB, TH
Final approval of the article: SS, CC, DR, MD, AB, RF,
SB, TH
Statistical analysis: DR, MD
Obtained funding: Not applicable
Overall responsibility: SS
SS and CC share co-ﬁrst authorship.
REFERENCES
1. Goff CD, Sato DT, Bloch PH, DeMasi RJ, Gregory RT, Gayle RG,
et al. Steal syndrome complicating hemodialysis access procedures: can
it be predicted? Ann Vasc Surg 2000;14:138-44.
JOURNAL OF VASCULAR SURGERY
458 Scali et al February 20132. Hurton S, Embil JM, Reda A, Smallwood S, Wall C, Thomson L, et al.
Upper extremity complications in patients with chronic renal failure
receiving haemodialysis. J Ren Care 2010;36:203-11.
3. Tordoir JH, Dammers R, van der Sande FM. Upper extremity ischemia
and hemodialysis vascular access. Eur J Vasc Endovasc Surg 2004;27:1-5.
4. Papasavas PK, Reifsnyder T, Birdas TJ, Caushaj PF, Leers S. Prediction
of arteriovenous access steal syndrome utilizing digital pressure
measurements. Vasc Endovasc Surg 2003;37:179-84.
5. Keuter XH, Kessels AG, de Haan MH, van der Sande FM, Tordoir JH.
Prospective evaluation of ischemia in brachial-basilic and forearm
prosthetic arteriovenous ﬁstulas for hemodialysis. Eur J Vasc Endovasc
Surg 2008;35:619-24.
6. Lazarides MK, Staramos DN, Kopadis G, Maltezos C, Tzilalis VD,
Georgiadis GS. Onset of arterial ‘steal’ following proximal angioaccess:
Immediate and delayed types. Nephrol Dial Transplant 2003;18:
2387-90.
7. Morsy AH, Kulbaski M, Chen C, Isiklar H, Lumsden AB. Incidence
and characteristics of patients with hand ischemia after a hemodialysis
access procedure. J Surg Res 1998;74:8-10.
8. Schanzer H, Schwartz M, Harrington E, Haimov M. Treatment of
ischemia due to “steal” by arteriovenous ﬁstula with distal artery liga-
tion and revascularization. J Vasc Surg 1988;7:770-3.
9. Schanzer H, Eisenberg D. Management of steal syndrome resulting
from dialysis access. Semin Vasc Surg 2004;17:45-9.
10. Gupta N, Yuo TH, Konig Gt, Dillavou E, Leers SA, Chaer RA, et al.
Treatment strategies of arterial steal after arteriovenous access. J Vasc
Surg 2011;54:162-7.
11. Huber TS, Brown MP, Seeger JM, Lee WA. Midterm outcome after
the distal revascularization and interval ligation (DRIL) procedure.
J Vasc Surg 2008;48:926-32; discussion: 932-3.
12. Knox RC, Berman SS, Hughes JD, Gentile AT, Mills JL. Distal
revascularization-interval ligation: a durable and effective treatment for
ischemic steal syndrome after hemodialysis access. J Vasc Surg 2002;36:
250-5; discussion: 256.
13. Balaji S, Evans JM, Roberts DE, Gibbons CP. Treatment of steal
syndrome complicating a proximal arteriovenous bridge graft ﬁstula by
simple distal artery ligation without revascularization using intra-
operative pressure measurements. Ann Vasc Surg 2003;17:320-2.
14. Minion DJ, Moore E, Endean E. Revision using distal inﬂow: a novel
approach to dialysis-associated steal syndrome. Ann Vasc Surg
2005;19:625-8.
15. Diehl L, Johansen K, Watson J. Operative management of distal
ischemia complicating upper extremity dialysis access. Am J Surg
2003;186:17-9.
16. Korzets A, Kantarovsky A, Lehmann J, Sachs D, Gershkovitz R,
Hasdan G, et al. The “DRIL” procedureda neglected way to treat the
“steal” syndrome of the hemodialysed patient. Isr Med Assoc J 2003;5:
782-5.
17. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T,
Andreucci VE, et al. Association of comorbid conditions and mortality
in hemodialysis patients in Europe, Japan, and the United States: The
Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc
Nephrol 2003;14:3270-7.
18. Huber TS, Ozaki CK, Flynn TC, Lee WA, Berceli SA, Hirneise CM,
et al. Prospective validation of an algorithm to maximize native arte-
riovenous ﬁstulae for chronic hemodialysis access. J Vasc Surg 2002;36:
452-9.19. Huber TS, Hirneise CM, Lee WA, Flynn TC, Seeger JM. Outcome
after autogenous brachial-axillary translocated superﬁcial femo-
ropopliteal vein hemodialysis access. J Vasc Surg 2004;40:311-8.
20. Sidawy AN, Spergel LM, Besarab A, Allon M, Jennings WC,
Padberg FT Jr, et al. The Society for Vascular Surgery: clinical practice
guidelines for the surgical placement and maintenance of arteriovenous
hemodialysis access. J Vasc Surg 2008;48:2S-25S.
21. Scali ST, Huber TS. Treatment strategies for access-related hand
ischemia. Semin Vasc Surg 2011;24:128-36.
22. Berman SS, Gentile AT, Glickman MH, Mills JL, Hurwitz RL,
Westerband A, et al. Distal revascularization-interval ligation for limb
salvage and maintenance of dialysis access in ischemic steal syndrome.
J Vasc Surg 1997;26:393-402; discussion: 402-4.
23. Seeger JM, Pretus HA, Carlton LC, Flynn TC, Ozaki CK, Huber TS.
Potential predictors of outcome in patients with tissue loss who
undergo infrainguinal vein bypass grafting. J Vasc Surg 1999;30:
427-35.
24. Gibson KD, Caps MT, Gillen D, Bergelin RO, Primozich J,
Strandness DE Jr. Identiﬁcation of factors predictive of lower extremity
vein graft thrombosis. J Vasc Surg 2001;33:24-31.
25. Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, et al.
Recommended standards for reports dealing with arteriovenous
hemodialysis accesses. J Vasc Surg 2002;35:603-10.
26. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in
epidemiology: possibilities and pitfalls. Int J Epidemiol 2012;41:861-70.
27. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing
risks and multi-state models. Stat Med 2007;26:2389-430.
28. Kim HT. Cumulative incidence in competing risks data and competing
risks regression analysis. Clin Cancer Res 2007;13:559-65.
29. Thermann F, Kornhuber M. Ischemic monomelic neuropathy: A rare
but important complication after hemodialysis access placementda
review. J Vasc Access 2011;12:113-9.
30. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L.
Risk factors, medical therapies and perioperative events in limb salvage
surgery: observations from the Prevent III Multicenter Trial. J Vasc
Surg 2005;42:456-64; discussion: 464-5.
31. Zanow J, Kruger U, Scholz H. Proximalization of the arterial inﬂow:
a new technique to treat access-related ischemia. J Vasc Surg 2006;43:
1216-21; discussion: 1221.
32. Zanow J, Petzold K, Petzold M, Krueger U, Scholz H. Flow reduction
in high-ﬂow arteriovenous access using intraoperative ﬂow monitoring.
J Vasc Surg 2006;44:1273-8.
33. Jennings WC. Creating arteriovenous ﬁstulas in 132 consecutive
patients: exploiting the proximal radial artery arteriovenous ﬁstula:
Reliable, safe, and simple forearm and upper arm hemodialysis access.
Arch Surg 2006;141:27-32; discussion: 32.
34. Shemesh D, Goldin I, Olsha O. Banding between dialysis puncture
sites to treat severe ischemic steal syndrome in low ﬂow autogenous
arteriovenous access. J Vasc Surg 2010;52:495-8.
35. KDOQI clinical practice guidelines for chronic kidney disease: evalu-
ation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis 2002;39:
S1-266.
36. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A,
et al. US Renal Data System 2010 annual data report. Am J Kidney Dis
2011;57:A8, e1-526.
Submitted Jul 16, 2012; accepted Aug 17, 2012.
